NASDAQ: MGTXMeiragtx Holdings PLC Stock
$5.22-0.15 (-2.79%)
Updated Nov 30, 2023
MGTX Price
$5.22
Fair Value Price
$6.93
Market Cap
$331.98M
52 Week Low
$3.49
52 Week High
$8.77
P/E
-2.11x
P/B
3.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$131.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.91
Operating Cash Flow
-$107M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGTX Overview
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGTX ($5.22) is undervalued by 24.66% relative to our estimate of its Fair Value price of $6.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MGTX ($5.22) is significantly undervalued by 24.66% relative to our estimate of its Fair Value price of $6.93 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MGTX due diligence checks available for Premium users.
Be the first to know about important MGTX news, forecast changes, insider trades & much more!
MGTX News
Valuation
MGTX fair value
Fair Value of MGTX stock based on Discounted Cash Flow (DCF)
Price
$5.22
Fair Value
$6.93
Undervalued by
24.66%
MGTX ($5.22) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MGTX ($5.22) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MGTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.11x
Industry
12.22x
Market
29.24x
MGTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.61x
Industry
5.4x
MGTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$44.3M
Profit Margin
0%
MGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$267.2M
Liabilities
$175.3M
Debt to equity
1.91
MGTX's short-term assets ($103.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGTX's long-term liabilities ($111.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.4M
Investing
-$3.6M
Financing
-$404.0k
MGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGTX vs Biotech Stocks
Meiragtx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.